T. Rowe Price Associates’s Colgate-Palmolive CL Stock Holding History

T. Rowe Price Associates’s Portfolio CL Stock Details CL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.87B	Buy	33,729,165 +2,541,888	+8%	+$227M	0.33%	53
2025 Q4	$2.46B	Sell	31,187,277 -1,154,744	-4%	-$90.5M	0.27%	72
2025 Q3	$2.59B	Sell	32,342,021 -4,206,156	-12%	-$359M	0.28%	69
2025 Q2	$3.32B	Buy	36,548,177 +2,539,099	+7%	+$232M	0.38%	43
2025 Q1	$3.19B	Buy	34,009,078 +5,269,140	+18%	+$472M	0.39%	44
2024 Q4	$2.61B	Sell	28,739,938 -2,153,628	-7%	-$206M	0.3%	58
2024 Q3	$3.21B	Sell	30,893,566 -7,359,188	-19%	-$750M	0.37%	49
2024 Q2	$3.71B	Sell	38,252,754 -2,814,376	-7%	-$260M	0.44%	39
2024 Q1	$3.7B	Buy	41,067,130 +8,933,912	+28%	+$757M	0.45%	40
2023 Q4	$2.56B	Buy	32,133,218 +4,625,472	+17%	+$348M	0.34%	56
2023 Q3	$1.96B	Buy	27,507,746 +10,231,592	+59%	+$765M	0.29%	66
2023 Q2	$1.33B	Buy	17,276,154 +13,961,123	+421%	+$1.08B	0.19%	110
2023 Q1	$249M	Buy	3,315,031 +698,307	+27%	+$51.9M	0.04%	342
2022 Q4	$206M	Buy	2,616,724 +30,834	+1%	+$2.31M	0.03%	375
2022 Q3	$182M	Buy	2,585,890 +79,153	+3%	+$6.21M	0.03%	381
2022 Q2	$201M	Buy	2,506,737 +234,113	+10%	+$18.3M	0.03%	479
2022 Q1	$172M	Sell	2,272,624 -293,925	-11%	-$23.3M	0.02%	572
2021 Q4	$219M	Sell	2,566,549 -662,526	-21%	-$51.7M	0.02%	535
2021 Q3	$244M	Sell	3,229,075 -29,757	-0.9%	-$2.36M	0.02%	481
2021 Q2	$265M	Sell	3,258,832 -1,037,469	-24%	-$84.8M	0.02%	481
2021 Q1	$339M	Sell	4,296,301 -1,863,600	-30%	-$146M	0.03%	411
2020 Q4	$527M	Buy	6,159,901 +138,990	+2%	+$11.5M	0.05%	316
2020 Q3	$465M	Buy	6,020,911 +118,177	+2%	+$9.01M	0.05%	313
2020 Q2	$432M	Buy	5,902,734 +1,973,189	+50%	+$140M	0.05%	317
2020 Q1	$261M	Buy	3,929,545 +1,723,878	+78%	+$122M	0.04%	354
2019 Q4	$152M	Sell	2,205,667 -291,889	-12%	-$19.9M	0.02%	546
2019 Q3	$184M	Sell	2,497,556 -38,509	-2%	-$2.79M	0.03%	471
2019 Q2	$182M	Buy	2,536,065 +11,319	+0.4%	+$804K	0.03%	487
2019 Q1	$173M	Buy	2,524,746 +408,071	+19%	+$26.4M	0.03%	507
2018 Q4	$126M	Sell	2,116,675 -4,644	-0.2%	-$291K	0.02%	548
2018 Q3	$142M	Sell	2,121,319 -284,632	-12%	-$19M	0.02%	572
2018 Q2	$156M	Sell	2,405,951 -397,071	-14%	-$26M	0.02%	536
2018 Q1	$201M	Sell	2,803,022 -519,176	-16%	-$37.4M	0.03%	457
2017 Q4	$251M	Sell	3,322,198 -1,558,422	-32%	-$114M	0.04%	411
2017 Q3	$356M	Sell	4,880,620 -2,097,048	-30%	-$151M	0.06%	328
2017 Q2	$517M	Sell	6,977,668 -126,219	-2%	-$9.37M	0.09%	240
2017 Q1	$520M	Buy	7,103,887 +3,195,278	+82%	+$224M	0.1%	234
2016 Q4	$256M	Buy	3,908,609 +13,773	+0.4%	+$944K	0.05%	365
2016 Q3	$289M	Buy	3,894,836 +387,697	+11%	+$28.7M	0.06%	320
2016 Q2	$257M	Sell	3,507,139 -23,082	-0.7%	-$1.64M	0.05%	346
2016 Q1	$249M	Buy	3,530,221 +102,641	+3%	+$6.83M	0.05%	347
2015 Q4	$228M	Buy	3,427,580 +93,490	+3%	+$6.22M	0.05%	365
2015 Q3	$212M	Buy	3,334,090 +292,693	+10%	+$19.1M	0.05%	398
2015 Q2	$199M	Buy	3,041,397 +579,161	+24%	+$39.3M	0.04%	448
2015 Q1	$171M	Sell	2,462,236 -31,098	-1%	-$2.15M	0.04%	469
2014 Q4	$173M	Sell	2,493,334 -59,824	-2%	-$4.04M	0.04%	469
2014 Q3	$167M	Buy	2,553,158 +19,347	+0.8%	+$1.28M	0.04%	465
2014 Q2	$173M	Sell	2,533,811 -2,564	-0.1%	-$172K	0.04%	482
2014 Q1	$165M	Buy	2,536,375 +45,713	+2%	+$2.88M	0.04%	486
2013 Q4	$162M	Sell	2,490,662 -518,488	-17%	-$33.2M	0.04%	481
2013 Q3	$178M	Sell	3,009,150 -3,781,946	-56%	-$224M	0.04%	428
2013 Q2	$389M	Buy	+6,791,096	New	+$403M	0.1%	243

Other funds holding CL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DAM

Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

T. Rowe Price Associates's CL Position: Q1 2026 in Review

T. Rowe Price Associates increased its Colgate-Palmolive (CL) stake by 8.2% in Q1 2026, buying an estimated $227M and bringing the position to 33,729,165 shares worth $2.87B. The position accounts for 0.33% of the portfolio, ranked #53.

T. Rowe Price Associates first reported a position in CL in Q2 2013 and has held it in 52 quarters since. The position peaked at $3.71B in Q2 2024. 1,945 funds tracked by Wall St. Rank hold CL as of Q1 2026.

T. Rowe Price Associates held 33,729,165 shares of Colgate-Palmolive worth $2.87B as of Q1 2026.
T. Rowe Price Associates bought 2,541,888 Colgate-Palmolive shares in Q1 2026, an estimated $227M.
Colgate-Palmolive made up 0.33% of T. Rowe Price Associates's portfolio in Q1 2026, its #53 holding.
T. Rowe Price Associates first reported a position in Colgate-Palmolive in Q2 2013 and has held it in 52 quarters since.
T. Rowe Price Associates's Colgate-Palmolive position peaked at $3.71B in Q2 2024.
1,945 funds tracked by Wall St. Rank held Colgate-Palmolive as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.